US Patent Issued to Theravance Biopharma R&D IP on July 15 for "3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1octan-8-yl) propanenitrile as a JAK kinase inhibitor" (California Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,358,931, issued on July 15, was assigned to Theravance Biopharma R&D IP LLC (South San Francisco, Calif.).

"3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1octan-8-yl) propanenitrile as a JAK kinase inhibitor" was invented by Ryan Hudson (San Mateo, Calif.), Jennifer Kozak (Pacifica, Calif.), Paul R. Fatheree (San Francisco), Dante D. Podesto (Modesto, Calif.), Gary E. L. Brandt (Alameda, Calif.), Melissa Fleury (Brisbane, Calif.) and Anne-Marie Beausoleil (San Mateo, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is a compound of the formula:or a pharmaceutically-acceptable salt ther...